EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)

Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis

Luca Richeldi, Arata Azuma, Vincent Cottin iD, Michael Kreuter, Toby M Maher, Fernando J Martinez, Justin M Oldham, Claudia Valenzuela, Emmanuelle Clerisme-Beaty, Maud Gordat, Daniel Wachtlin, Yi Liu und 5 weitere

New England Journal of Medicine · 12.06.2025 · 392 (22) · 2193-2202

DOI: 10.1056/nejmoa2414108 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 12.06.2025. Verfasst von Luca Richeldi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Unità Operativa Complessa di Pneumologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Phosphodiesterase 4 Inhibitors. Die Arbeit wurde bisher 302-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Idiopathic Pulmonary FibrosisPhosphodiesterase 4 InhibitorsAgedFemaleHumansMaleMiddle AgedDouble-Blind MethodLungVital CapacityAntifibrotic AgentsTreatment OutcomeDisease ProgressionDose-Response Relationship, DrugTabletsAdministration, OralCyclobutanesIndolesPyridonesOrganic ChemicalsPiperidines

Substanzen

nintedanibPhosphodiesterase 4 InhibitorspirfenidoneBI 1015550Antifibrotic AgentsTabletsCyclobutanesIndolesPyridonesOrganic Chemicals

Autor:innen und Institutionen

  • Unità Operativa Complessa di Pneumologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome.
  • Clinical Research Center, Mihara General Hospital, Saitama, Japan.
  • Nippon Medical School, Tokyo.
  • National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon 1, Unité Mixte de Recherche 754, European Reference Network for Rare Respiratory Dise…
  • Center for Pulmonary Medicine, Department of Pneumology, Mainz University Medical Center, Mainz, Germany.
  • Pulmonary, Critical Care, and Sleep Medicine, Marienhaus Clinic Mainz, Mainz, Germany.

ORCID-Profile: Vincent Cottin, Marlies S Wijsenbeek

Zitieren

APA

Richeldi, L., Azuma, A., Cottin, V., Kreuter, M., Maher, T. M., Martinez, F. J., Oldham, J. M., Valenzuela, C., Clerisme-Beaty, E., Gordat, M., Wachtlin, D., Liu, Y., Schlecker, C., Stowasser, S., Zoz, D. F., Wijsenbeek, M. S., & FIBRONEER-IPF Trial Investigators (2025). Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 392(22), 2193-2202. https://doi.org/10.1056/nejmoa2414108

Vancouver

Richeldi L, Azuma A, Cottin V, Kreuter M, Maher TM, Martinez FJ, et al. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. New England Journal of Medicine. 2025;392(22):2193-2202. doi:10.1056/nejmoa2414108

BibTeX
@article{Richeldi2025,
  author = {Richeldi, Luca and Azuma, Arata and Cottin, Vincent and Kreuter, Michael and Maher, Toby M and Martinez, Fernando J and Oldham, Justin M and Valenzuela, Claudia and Clerisme-Beaty, Emmanuelle and Gordat, Maud and Wachtlin, Daniel and Liu, Yi and Schlecker, Christina and Stowasser, Susanne and Zoz, Donald F and Wijsenbeek, Marlies S and FIBRONEER-IPF Trial Investigators, FIBRONEER-IPF Trial Investigators},
  title = {Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {392},
  number = {22},
  pages = {2193--2202},
  doi = {10.1056/nejmoa2414108}
}
Kostenlos starten →